Pathophysiology and management of thrombosis in cancer: 150 years of progress

Journal of Thrombosis and Thrombolysis

Volumn 35, Issue 3, 2013, Pages 346-351

  Soff, Gerald A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cancer; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; SEMULOPARIN; THROMBOPLASTIN; WARFARIN;

BLEEDING; BLOOD CLOTTING; CANCER CELL; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; HEART ATRIUM FIBRILLATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; MEMBRANE MICROPARTICLE; NEOPLASM; ONCOGENE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; TUMOR SUPPRESSOR GENE; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEOPLASMS; THROMBOSIS; WARFARIN;

EID: 84876684978     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0897-9     Document Type: Conference Paper

References (51)

1. Khorana AA (2003) Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost 1:2463-2465
2. Trousseau A (1865) Clinique Medicale de l'Hotel-Dieu de Paris. Bailliere Tindall, Paris
3. Heit JA (2005) Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 3:1611-1617 (Pubitemid 41716546)
4. Hillen HF (2000) Thrombosis in cancer patients. Ann Oncol 11(Suppl 3):273-276
5. Prandoni P (2005) How I treat venous thromboembolism in patients with cancer. Blood 106:4027-4033 (Pubitemid 41775905)
6. Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. Lancet Oncol 6:401-410 (Pubitemid 40753746)
7. Shen VS, Pollak EW (1980) Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 73:841-843 (Pubitemid 11000639)
8. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632-634 (Pubitemid 46680709)
9. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850 (Pubitemid 32104130)
10. Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715-722 (Pubitemid 40216041)
11. Boccaccio C, Comoglio PM (2009) Genetic link between cancer and thrombosis. J Clin Oncol 27:4827-4833
12. Mackman N (2009) The many faces of tissue factor. J Thromb Haemost 7(Suppl 1):136-139
13. Mackman N, Taubman M (2009) Tissue factor: past, present, and future. Arterioscler Thromb Vasc Biol 29:1986-1988
14. Nitori N, Ino Y, Nakanishi Y, Yamada T, Honda K, Yanagihara K, Kosuge T, Kanai Y, Kitajima M, Hirohashi S (2005) Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 11:2531-2539 (Pubitemid 40569450)
15. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T (2000) Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 83:164-170 (Pubitemid 30411712)
16. Goldin-Lang P, Tran QV, Fichtner I, Eisenreich A, Antoniak S, Schulze K, Coupland SE, Poller W, Schultheiss HP, Rauch U (2008) Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep 20:123-128
17. Rak J (2010) Microparticles in cancer. Semin Thromb Hemost 36:888-906
18. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B (2009) Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15:6830-6840
19. Zwicker JI (2010) Predictive value of tissue factor bearing microparticles in cancer associated thrombosis. Thromb Res 125(Suppl 2):S89-S91
20. Zwicker JI, Trenor CC 3rd, Furie BC, Furie B (2011) Tissue factor-bearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol 31:728-733
21. Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, Hostetter G, Harvey J, Taubman MB (2007) Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 13:2870-2875 (Pubitemid 46849560)
22. Falanga A (2005) The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica 90:149
23. Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Consonni R, Caccia R, Longatti S, Maran D, Rodeghiero F, Pogliani E et al (1993) Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 85:745-750 (Pubitemid 24003590)
24. Edwards RL, Rickles FR, Moritz TE, Henderson WG, Zacharski LR, Forman WB, Cornell CJ, Forcier RJ, O'Donnell JF, Headley E et al (1987) Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 88:596-602 (Pubitemid 18014618)
25. Falanga A (2005) Thrombophilia in cancer. Semin Thromb Hemost 31:104-110 (Pubitemid 40262144)
26. Rickles FR, Falanga A (2001) Molecular basis for the relationship between thrombosis and cancer. Thromb Res 102:V215-V224 (Pubitemid 32539212)
27. Hyman DM, Soff GA, Kampel LJ (2011) Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature. Oncology 81:119-125
28. Barritt DW, Jordan SC (1960) Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1:1309-1312
29. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484-3488 (Pubitemid 35303914)
30. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:160S-198S (Pubitemid 351892967)
31. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146-153 (Pubitemid 36818784)
32. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12:389-396 (Pubitemid 44359237)
33. Linkins LA (2008) Management of venous thromboembolism in patients with cancer: role of dalteparin. Vasc Health Risk Manag 4:279-287
34. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162:1729-1735
35. Lee AY (2009) Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol 27:4895-4901
36. Browne AM, Cronin CG, English C, NiMhuircheartaigh J, Murphy JM, Bruzzi JF (2010) Unsuspected pulmonary emboli in oncology patients undergoing routine computed tomography imaging. J Thorac Oncol. 5:798-803
37. Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP (2010) Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost 8:1702-1709
38. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, Soff G, Parameswaran R, Hassoun H (2011) High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 29:3466-3473
39. den Exter PL, Hooijer J, Dekkers OM, Huisman MV (2011) Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 29:2405-2409
40. Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA (2011) Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost 106:371-378
41. Font C, Farrus B, Vidal L, Caralt TM, Visa L, Mellado B, Tassies D, Monteagudo J, Reverter JC, Gascon P (2011) Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Ann Oncol 22:2101-2106
42. Warkentin TE, Greinacher A, Koster A, Lincoff AM (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:340S-380S (Pubitemid 351892970)
43. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006) Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759-765
44. Herishanu Y, Misgav M, Kirgner I, Ben-Tal O, Eldor A, Naparstek E (2004) Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens. Leuk Lymphoma 45:1407-1411 (Pubitemid 38701918)
45. Ibrahim RB, Peres E, Dansey R, Abidi MH, Abella EM, Gumma MM, Milan N, Smith DW, Heilbrun LK, Klein J (2005) Safety of low-dose low-molecular-weight- heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature. Bone Marrow Transplant 35:1071-1077 (Pubitemid 40767195)
46. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505 (Pubitemid 350232226)
47. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366:601-609
48. Khorana AA, Connolly GC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27:4839-4847
49. Soff GA (2012) A new generation of oral direct anticoagulants. Arterioscler Thromb Vasc Biol 32:569-574
50. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499-2510
51. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287-1297